Da	te:_August 29, 2021			
	ur Name:_Yu-Fang Tang			
			Aberrant IncRNA-miRNA-mRNA Network Based on Compe	titive
	dogenous RNA in Adenoid C	-		
Ma	anuscript number (if known)): TCR-21-1771		_
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d to the author's relationsh ivities/interests should be ension, you should declar cation is not mentioned in	nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertain e all relationships with manufacturers of antihypertensive	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
1	All support for the present	X None	priming of the north	
-	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.) No time limit for this item.			
	No time illinic for tims item.			
		Time frame: pas	st 36 months	
2	Grants or contracts from	_ X _None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	_ X _None		

X _None

Consulting fees

4

5	Payment or honoraria for lectures, presentations,	_ X _None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or	_ X _None	
	pending		
0	5 5		
9	Participation on a Data	_ X _None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_ ^ _None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

I have no conflicts of interest to declare.				

Please place an "X" next to the following statement to indicate your agreement:

Da	te:_August 29, 2021			
	ur Name:_Wen-Jie Wu			
		ction and Analysis of the A	Aberrant IncRNA-miRNA-mRNA Network Based on Com	npetitive
	dogenous RNA in Adenoid C	· · · · · · · · · · · · · · · · · · ·		
	anuscript number (if known)			
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmen . If you are in doubt about whether to list a o so.	
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current	
to	•	ension, you should declare	defined broadly. For example, if your manuscript pert all relationships with manufacturers of antihypertens the manuscript.	
	item #1 below, report all su e time frame for disclosure i	•	ed in this manuscript without time limit. For all other i	tems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	al planning of the work	
	All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		T: f	4.2C	
		Time frame: pas	t 36 months	
<u>'</u>	Grants or contracts from	_ X _None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	_ X _None		

X _None

4

Consulting fees

5	Payment or honoraria for lectures, presentations,	_ X _None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or	_ X _None	
	pending		
0	5 5		
9	Participation on a Data	_ X _None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_ ^ _None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

I have no conflicts of interest to declare.				

Please place an "X" next to the following statement to indicate your agreement:

Da	nte:_August 29, 2021			
Υo	ur Name: Jian-Yun Zhang			
		ction and Analysis of the A	Aberrant IncRNA-miRNA-mRNA Network Based on Comp	etitive
	dogenous RNA in Adenoid C			
	anuscript number (if known)	-		
re pa to	lated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.	
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current	
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript perta e all relationships with manufacturers of antihypertension the manuscript.	
	item #1 below, report all sup e time frame for disclosure is	•	ed in this manuscript without time limit. For all other ite	ems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	institution	
		needed)		
		Time frame: Since the initia	al planning of the work	
	All support for the present	X None		
	manuscript (e.g., funding,	XNone		
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time from a rec	at 2C months	
	Grants or contracts from	Time frame: pas	or 50 months	
		X _None		
	any entity (if not indicated			
	in item #1 above)			
	in item #1 above). Royalties or licenses	X None		

Consulting fees

X _None

4

5	Payment or honoraria for lectures, presentations,	_ X _None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or	_ X _None	
	pending		
0	5 5		
9	Participation on a Data	_ X _None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_ ^ _None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

I have no conflicts of interest to declare.				

Please place an "X" next to the following statement to indicate your agreement:

Da	te:_August 29, 2021			
Υo	ur Name: Jie Zhang			
Ma	anuscript Title: Reconstru	ction and Analysis of the	Aberrant IncRNA-miRNA-mRNA Network Based on Co	mpetitive
	dogenous RNA in Adenoid C			•
	nuscript number (if known)	•	•	
rel pa to rel The ma The to me	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply muscript only. e author's relationships/activite epidemiology of hypertedication, even if that medications	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d to the author's relationsh ivities/interests should be ension, you should declare ation is not mentioned in	nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript per e all relationships with manufacturers of antihyperten	nt tains sive
		Name all entities with	Specifications/Comments	1
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	motitudion,	
		needed)		
		Time frame: Since the initia	al planning of the work	
	All support for the present	_ X _None		
	manuscript (e.g., funding,			1
	provision of study materials,			1
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			1
				1
				1
		Time frame: pas	st 36 months	
	Grants or contracts from	X None		
	any entity (if not indicated			1
	in item #1 above).			1
	Royalties or licenses	X None		1

Consulting fees

X _None

4

5	Payment or honoraria for lectures, presentations,	_ X _None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_ X _None	
8	Patents planned, issued or	_ X _None	
	pending		
0	5 5		
9	Participation on a Data	_ X _None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_ ^ _None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ X _None	
12	Receipt of equipment,	_ X _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ X _None	
	financial interests		

I have no conflicts of interest to declare.				

Please place an "X" next to the following statement to indicate your agreement: